WO2011122389A1 - 糖尿病の予防又は治療用油脂組成物 - Google Patents
糖尿病の予防又は治療用油脂組成物 Download PDFInfo
- Publication number
- WO2011122389A1 WO2011122389A1 PCT/JP2011/056710 JP2011056710W WO2011122389A1 WO 2011122389 A1 WO2011122389 A1 WO 2011122389A1 JP 2011056710 W JP2011056710 W JP 2011056710W WO 2011122389 A1 WO2011122389 A1 WO 2011122389A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- oil
- fatty acid
- lct
- test
- fat composition
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 59
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 22
- 230000002265 prevention Effects 0.000 title abstract description 11
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 38
- 239000000194 fatty acid Substances 0.000 claims abstract description 38
- 229930195729 fatty acid Natural products 0.000 claims abstract description 38
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 claims abstract description 36
- 150000004665 fatty acids Chemical class 0.000 claims abstract description 31
- 150000004667 medium chain fatty acids Chemical group 0.000 claims abstract description 24
- 239000004480 active ingredient Substances 0.000 claims abstract description 21
- 150000004668 long chain fatty acids Chemical class 0.000 claims abstract description 16
- 125000004432 carbon atom Chemical group C* 0.000 claims description 21
- 239000000470 constituent Substances 0.000 claims description 18
- 235000013305 food Nutrition 0.000 claims description 15
- 150000004671 saturated fatty acids Chemical class 0.000 claims description 4
- 230000000694 effects Effects 0.000 abstract description 16
- 150000003626 triacylglycerols Chemical class 0.000 abstract description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 96
- 239000003921 oil Substances 0.000 description 65
- 235000019198 oils Nutrition 0.000 description 65
- 238000012360 testing method Methods 0.000 description 56
- 239000003925 fat Substances 0.000 description 53
- 235000019197 fats Nutrition 0.000 description 50
- 102000004877 Insulin Human genes 0.000 description 48
- 108090001061 Insulin Proteins 0.000 description 48
- 229940125396 insulin Drugs 0.000 description 48
- 241000700159 Rattus Species 0.000 description 40
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 30
- 239000008103 glucose Substances 0.000 description 30
- 229960001031 glucose Drugs 0.000 description 30
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 29
- 206010022489 Insulin Resistance Diseases 0.000 description 23
- 238000004519 manufacturing process Methods 0.000 description 21
- 230000003914 insulin secretion Effects 0.000 description 17
- 210000004369 blood Anatomy 0.000 description 16
- 239000008280 blood Substances 0.000 description 16
- 230000037406 food intake Effects 0.000 description 16
- 230000037396 body weight Effects 0.000 description 15
- 235000012631 food intake Nutrition 0.000 description 15
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 14
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 14
- 238000005259 measurement Methods 0.000 description 12
- 238000000034 method Methods 0.000 description 11
- 239000003814 drug Substances 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 238000005809 transesterification reaction Methods 0.000 description 9
- 108010076365 Adiponectin Proteins 0.000 description 8
- 102000011690 Adiponectin Human genes 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 230000009471 action Effects 0.000 description 8
- -1 fatty acid triacylglycerols Chemical class 0.000 description 8
- 238000000692 Student's t-test Methods 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 239000000828 canola oil Substances 0.000 description 6
- 235000019519 canola oil Nutrition 0.000 description 6
- 235000005911 diet Nutrition 0.000 description 6
- 230000037213 diet Effects 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 238000007446 glucose tolerance test Methods 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 210000001596 intra-abdominal fat Anatomy 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 210000003462 vein Anatomy 0.000 description 6
- 230000004584 weight gain Effects 0.000 description 6
- 235000019786 weight gain Nutrition 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 102000004882 Lipase Human genes 0.000 description 5
- 108090001060 Lipase Proteins 0.000 description 5
- 239000004367 Lipase Substances 0.000 description 5
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 5
- 229940098773 bovine serum albumin Drugs 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 238000005886 esterification reaction Methods 0.000 description 5
- 235000019421 lipase Nutrition 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 238000009395 breeding Methods 0.000 description 4
- 230000001488 breeding effect Effects 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 231100000957 no side effect Toxicity 0.000 description 4
- 238000007410 oral glucose tolerance test Methods 0.000 description 4
- 230000000384 rearing effect Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 201000010063 epididymitis Diseases 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 238000012528 insulin ELISA Methods 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 229910001220 stainless steel Inorganic materials 0.000 description 3
- 239000010935 stainless steel Substances 0.000 description 3
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 2
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 229940127003 anti-diabetic drug Drugs 0.000 description 2
- 239000003472 antidiabetic agent Substances 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 235000008429 bread Nutrition 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000013065 commercial product Substances 0.000 description 2
- 235000005687 corn oil Nutrition 0.000 description 2
- 239000002285 corn oil Substances 0.000 description 2
- 210000000028 corpus adiposum pararenale Anatomy 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 235000013345 egg yolk Nutrition 0.000 description 2
- 210000002969 egg yolk Anatomy 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000009207 exercise therapy Methods 0.000 description 2
- 235000021050 feed intake Nutrition 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000004817 gas chromatography Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 235000009200 high fat diet Nutrition 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000013310 margarine Nutrition 0.000 description 2
- 239000003264 margarine Substances 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- FBUKVWPVBMHYJY-UHFFFAOYSA-N nonanoic acid Chemical compound CCCCCCCCC(O)=O FBUKVWPVBMHYJY-UHFFFAOYSA-N 0.000 description 2
- SECPZKHBENQXJG-FPLPWBNLSA-N palmitoleic acid Chemical compound CCCCCC\C=C/CCCCCCCC(O)=O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 description 2
- 238000001050 pharmacotherapy Methods 0.000 description 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 235000021067 refined food Nutrition 0.000 description 2
- 235000003441 saturated fatty acids Nutrition 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical compound CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- 235000021357 Behenic acid Nutrition 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 239000004129 EU approved improving agent Substances 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 108700037728 Glycine max beta-conglycinin Proteins 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 229940122199 Insulin secretagogue Drugs 0.000 description 1
- 244000017020 Ipomoea batatas Species 0.000 description 1
- 235000002678 Ipomoea batatas Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000021353 Lignoceric acid Nutrition 0.000 description 1
- CQXMAMUUWHYSIY-UHFFFAOYSA-N Lignoceric acid Natural products CCCCCCCCCCCCCCCCCCCCCCCC(=O)OCCC1=CC=C(O)C=C1 CQXMAMUUWHYSIY-UHFFFAOYSA-N 0.000 description 1
- 101000775476 Mus musculus Adiponectin Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 235000021319 Palmitoleic acid Nutrition 0.000 description 1
- 235000004347 Perilla Nutrition 0.000 description 1
- 244000124853 Perilla frutescens Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 208000021017 Weight Gain Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 229940116226 behenic acid Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- SECPZKHBENQXJG-UHFFFAOYSA-N cis-palmitoleic acid Natural products CCCCCCC=CCCCCCCCC(O)=O SECPZKHBENQXJG-UHFFFAOYSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 238000004332 deodorization Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 235000012489 doughnuts Nutrition 0.000 description 1
- 235000015071 dressings Nutrition 0.000 description 1
- 229940029980 drug used in diabetes Drugs 0.000 description 1
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 1
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 1
- 235000015897 energy drink Nutrition 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- FARYTWBWLZAXNK-WAYWQWQTSA-N ethyl (z)-3-(methylamino)but-2-enoate Chemical compound CCOC(=O)\C=C(\C)NC FARYTWBWLZAXNK-WAYWQWQTSA-N 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000013611 frozen food Nutrition 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 description 1
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 1
- 235000020664 gamma-linolenic acid Nutrition 0.000 description 1
- 229960002733 gamolenic acid Drugs 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- 239000000944 linseed oil Substances 0.000 description 1
- 235000021388 linseed oil Nutrition 0.000 description 1
- 235000021056 liquid food Nutrition 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000008268 mayonnaise Substances 0.000 description 1
- 235000010746 mayonnaise Nutrition 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 108010071421 milk fat globule Proteins 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000000199 molecular distillation Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 235000012459 muffins Nutrition 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 229960002969 oleic acid Drugs 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 235000020830 overeating Nutrition 0.000 description 1
- 239000003346 palm kernel oil Substances 0.000 description 1
- 235000019865 palm kernel oil Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229960005095 pioglitazone Drugs 0.000 description 1
- 235000002378 plant sterols Nutrition 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 235000020991 processed meat Nutrition 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 108700002051 rat Adipoq Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 235000011496 sports drink Nutrition 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 235000000891 standard diet Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000021195 test diet Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 125000003203 triacylglycerol group Chemical group 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 239000008256 whipped cream Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the present invention relates to an oil or fat composition for prevention or treatment of diabetes, and in particular, to an oil or fat composition for prevention or treatment of diabetes containing a specific triacylglycerol as an active ingredient.
- Diabetes is roughly classified into type I diabetes (insulin-dependent diabetes) and type II diabetes (non-insulin-dependent diabetes). Most people with diabetes in Japan have type II diabetes, and symptoms such as insulin secretion deficiency in which the amount of insulin secreted decreases and insulin resistance (insulin deficiency) in which the action to lower blood sugar of insulin weakens progress. It develops by. These symptoms are greatly related to genetic factors and environmental factors such as unbalanced diet, overeating, lack of exercise, and stress.
- type II diabetes In general, treatment of type II diabetes is based on diet therapy and exercise therapy, and drug therapy is performed.
- sulfonylurea agents SU agents
- thiazolidine drugs such as pioglitazone are used.
- SU drugs have side effects such as hypoglycemia, pruritus, rash, weight gain, pancreatic ⁇ -cell exhaustion, and thiazolidine drugs are contraindicated in patients with hepatic or renal dysfunction. And had problems of side effects such as edema and weight gain. Since it is necessary to carry out pharmacotherapy of diabetes continuously for a long period of time, it has been desired to develop an antidiabetic drug that does not have a side effect even if it is continuously taken.
- an insulin secretagogue (patent document 1) containing as an active ingredient an extract obtained from the skin portion of white sweet potato tuber, acetic acid, ⁇ -conglycinin, and ⁇ -amino Insulin resistance improving agents containing butyric acid as active ingredients have been reported (Patent Documents 2 to 4).
- the present invention has been made in view of the above circumstances, and the object thereof is an oil and fat composition effective for the prevention or treatment of diabetes, which is highly safe and has no side effects even when continuously ingested, and It is to provide food and drink containing it.
- the present inventor has conducted extensive studies to solve the above-mentioned problems.
- a constituent fatty acid triacylglycerol having a medium-chain fatty acid and a long-chain fatty acid having a specific carbon number in the molecule is used as an active ingredient.
- the oil-and-fat composition it discovered that the said subject could be solved and came to complete this invention.
- the present invention provides the following.
- Triacylglycerol is contained as an active ingredient, and the triacylglycerol has one or two medium chain fatty acid residues in the molecule, and the medium fatty acid having 6 to 10 carbon atoms as a constituent fatty acid.
- a fat or oil composition for preventing or treating diabetes comprising a fatty acid and a long-chain fatty acid having 16 to 24 carbon atoms.
- the oil and fat composition of the present invention has an insulin secretion promoting action and an insulin resistance improving action, insulin secretion failure in which the amount of insulin secretion is reduced, or diabetes associated with insulin resistance in which the action of insulin is reduced or It is effective for treatment.
- the active ingredient is triacylglycerol
- the oil and fat composition of the present invention is highly safe and has no side effects, so it can be taken continuously with peace of mind.
- the oil and fat composition of the present invention is used for the prevention or treatment of diabetes and contains triacylglycerol as an active ingredient.
- the triacylglycerol which is an active ingredient of the oil and fat composition of the present invention, has one or two medium chain fatty acid residues in the molecule, and has 6 to 10 carbon atoms as a constituent fatty acid. And a long chain fatty acid having 16 to 24 carbon atoms. That is, as a form of triacylglycerol, a medium chain triacylglycerol (hereinafter referred to as MCT) in which only one medium chain fatty acid exists as a constituent fatty acid in one molecule of triacylglycerol, a long chain fatty acid only exists.
- MCT medium chain triacylglycerol
- LCT chain fatty acid triacylglycerols
- M ⁇ LCT medium and long chain fatty acid triacylglycerols
- the composition is characterized in that M ⁇ LCT containing, as a constituent fatty acid, a medium chain fatty acid having 6 to 10 carbon atoms and a long chain fatty acid having 16 to 24 carbon atoms as a constituent fatty acid is contained in one molecule of triacylglycerol.
- the oil and fat composition of the present invention may contain the MCT and / or LCT in addition to the M / LCT which is an active ingredient.
- a triacylglycerol is referred to as a medium-long chain fatty acid triacylglycerol (hereinafter referred to as MLCT), and has one or two medium-chain fatty acid residues in the molecule. It is expressed separately from M ⁇ LCT of triacylglycerol in which medium chain fatty acids and long chain fatty acids are mixed as fatty acids.
- Triacylglycerol as an active ingredient contains medium chain fatty acids having 6 to 10 carbon atoms and long chain fatty acids having 16 to 24 carbon atoms, and medium chain fatty acids having 6 to 10 carbon atoms and long chains having 16 to 24 carbon atoms. It preferably consists of fatty acids. Examples of medium chain fatty acids having 6 to 10 carbon atoms include n-hexanoic acid, n-heptanoic acid, n-octanoic acid, n-nonanoic acid, and n-decanoic acid. Saturated fatty acids having 8 and / or 10 carbon atoms (n-octanoic acid and / or n-decanoic acid) are more preferable. Medium chain fatty acids can be obtained by hydrolyzing coconut oil, palm kernel oil, and the like.
- Long chain fatty acids having 16 to 24 carbon atoms include long chain saturated fatty acids such as palmitic acid, stearic acid, arachidic acid, behenic acid, lignoceric acid, palmitoleic acid, oleic acid, linoleic acid, linolenic acid, ⁇ -linolenic acid, Long chain unsaturated fatty acids such as arachidonic acid and icosapentaenoic acid.
- Long chain fatty acids are obtained by squeezing the raw material for oil extraction and hydrolyzing the refined soybean oil, rapeseed oil, corn oil, rice oil, sesame oil, cottonseed oil, sunflower oil, safflower oil, linseed oil, perilla oil, olive oil, etc. Can do.
- the triacylglycerol which is an active ingredient of the oil and fat composition of the present invention, contains the above medium chain fatty acid and the above long chain fatty acid as constituent fatty acids, but the binding position of these fatty acids is not particularly limited.
- the method for producing triacylglycerol is not particularly limited, and examples thereof include a conventionally known transesterification reaction or esterification reaction.
- the transesterification include chemical transesterification using an inorganic catalyst such as sodium methoxide, and transesterification with an enzyme using lipase or the like. In the present invention, it does not particularly matter which reaction is caused. Further, the transesterification reaction may be either a selective transesterification reaction or a non-selective transesterification reaction, and is not particularly limited.
- esterification reaction examples include an esterification reaction using glycerin and a fatty acid, an esterification reaction using glycerin and a fatty acid ester, and an esterification reaction using glycerin and an oil. In the present invention, it does not particularly matter which reaction is caused.
- the proportion of the medium chain fatty acid in the total constituent fatty acids of triacylglycerol as an active ingredient is preferably 15 to 40% by mass, more preferably 20 to 35% by mass. preferable. If it is the said range, insulin secretion promotion effect
- a method for confirming the proportion of the medium chain fatty acid for example, after isolating the triacylglycerol from the oil and fat composition of the present invention by molecular distillation, column chromatography or the like, the constituent fatty acid is methyl esterified, The method of analyzing by gas chromatography is mentioned.
- a known emulsifier can be added in order to further improve the storage stability and the cooking ability within a range not impairing the effects of the present invention.
- synthetic emulsifiers such as polyglycerin fatty acid ester, sucrose fatty acid ester, sorbitan fatty acid ester, polysorbate, condensed ricinolein fatty acid ester, monoglycerin fatty acid ester, soybean lecithin, egg yolk lecithin, soybean lysolecithin, egg yolk lysolecithin, enzyme treatment
- Natural emulsifiers such as egg yolk, saponin, plant sterols, milk fat globule membrane and the like can be mentioned.
- the oil and fat composition of the present invention can be used to treat animals including humans who are required to increase the amount of insulin secreted or those who fall under the reserve arm, or humans who fall under diabetes or the reserve who needs to improve insulin resistance. It works effectively on animals that contain it. In particular, it is suitable for the prevention or treatment of type II diabetes accompanied by insulin secretion failure in which the amount of insulin secretion decreases and insulin resistance in which the action of insulin decreases.
- prevention means, for example, suppression or delay of onset
- treatment means, for example, delay of progression, alleviation, reduction, improvement, etc. of symptoms.
- Triacylglycerol and its constituent fatty acids, medium chain fatty acids and long chain fatty acids, which are contained as active ingredients in the oil and fat composition of the present invention, are widely present in nature, and are also included in edible natural products. ing. Therefore, the oil and fat composition of the present invention has high safety, and can be suitably used as pharmaceuticals (including those for animals), foods, feeds and the like.
- the oil and fat composition of the present invention contains triacylglycerol as an active ingredient with high safety and no side effects, so it can be taken safely and continuously even when used in pharmaceuticals. .
- the oil and fat composition of the present invention is suitable for drug therapy that combines diet therapy and exercise therapy performed in the treatment of type II diabetes because it is easy to control administration.
- Oral administration is preferable as an administration route when the oil and fat composition of the present invention is used as a pharmaceutical product. This is because most of the triacylglycerol, which is an active ingredient of the oil and fat composition of the present invention, is absorbed into the body through the mucous membrane of the intestinal tract (small intestine).
- the preparation suitable for oral administration include capsules, tablets, pills, powders, fine granules, granules, liquids, syrups and the like.
- the oil / fat composition of the present invention is preferably a preparation in the form of a pharmaceutical composition containing triacylglycerol as an active ingredient and pharmacologically and pharmaceutically acceptable additives.
- pharmacologically and pharmaceutically acceptable additives include excipients such as glucose, lactose, crystalline cellulose and starch, disintegrants, binders, coating agents, pigments, diluents, etc. Substances that are commonly used in the field and do not react with the active ingredient triacylglycerol are used.
- the oil and fat composition of the present invention is highly safe and has no side effects due to continuous use, by using it in combination with an existing drug, the dose of the existing drug can be reduced. It is possible to reduce side effects.
- Combinations with other drugs may be included in the same pharmaceutical composition as in the case of a combination drug, or may be included in separate pharmaceutical compositions.
- the dosage of a pharmaceutical using the oil and fat composition of the present invention can be appropriately selected according to various conditions such as patient symptoms, prevention or treatment, age, weight, administration method, administration period and the like.
- the effective amount is usually 200 to 1000 mg / kg body weight / day as triacylglycerol, which is an active ingredient, and this amount is given once.
- it may be administered in several divided doses, and may be adjusted as appropriate within this range depending on the timing of administration.
- the oil and fat composition of the present invention can be ingested as a food such as a health food or a nutritional supplement by filling and processing soft capsules.
- the oil and fat composition of the present invention is directly ingested as it is or by processing into powdered oil and fat, liquid emulsified oil and the like, or indirectly by using and processing these in general foods. You can also do it.
- the general food that can use the oil and fat composition of the present invention is not particularly limited as long as it is a processed food that uses oil and fat.
- a processed food that uses oil and fat For example, bread, cake, cookies, biscuits, donuts, muffins, scones , Chocolate, gummi, snacks, whipped cream, ice cream and other breads and confectionery, fruit juice drinks, energy drinks, sports drinks, soups, dressings, sauces, mayonnaise, butter, margarine, prepared margarine, etc.
- the oil and fat composition of the present invention is used for the production of food and drink consumed by a diabetic patient or its reserve army, for example, if it is an adult (body weight 60 kg), it is consumed by the type of food to be blended and others.
- the intake of the active ingredient triacylglycerol should be 200-1000 mg / kg body weight / day, depending on the intake timing, etc. Adjust it.
- MLCT (1) transesterified oil
- 2 g of MLCT (1) and 200 mg of bovine serum albumin are added to 10 ml of 40% glucose (D (+)-Glucose, manufactured by Wako Pure Chemical Industries, Ltd.), and the resulting solution is added. While cooling on ice, the sample was sonicated (2 sets of 5 minutes, total 10 minutes) to obtain Sample 2.
- Table 2 and Table 3 show the triacylglycerol composition and fatty acid composition of MLCT obtained in Production Example 2, respectively.
- the triacylglycerol composition was measured by gas chromatography using Silcone GS-1 manufactured by GL Sciences Inc. as the column, and the fatty acid composition was measured according to “Standard Oil Analysis Test Method (1996)”.
- the test consists of “LCT administration trial (sample 1 administration trial)” in which LCT is administered simultaneously with glucose load, and “MLCT (1) administration trial (sample 2 administration trial) in which MLCT (1) is administered simultaneously with glucose load. ”In two trials. Samples 1 and 2 were orally administered to rats using a sonde. The dose was 6 ⁇ l / g rat body weight. The final dose was 2 g and 1 g of carbohydrate and lipid per 1 kg body weight of the rat, respectively.
- Plasma insulin concentration (ng / ml) was measured.
- the plasma insulin concentration was measured by ELISA using a commercially available kit (trade name: Rat Insulin ELISA kit, manufactured by Mercodia).
- the test results are shown in FIG.
- the increase in plasma insulin concentration in the MLCT (1) administration trial was expressed as a relative value (%) where the average value of the increase in plasma insulin concentration in the LCT administration trial was 100, and expressed as an average value of the relative value ⁇ standard error. .
- the Student t-test test was used for the significant difference test between trials, and it was judged that there was a significant difference with a risk rate of less than 5%.
- the increase in plasma insulin concentration in the MLCT (1) administration trial was significantly higher (p ⁇ 0.01) than in the LCT administration trial. From this, it became clear that secretion of insulin is promoted according to the transesterified oil (MLCT) of MCT and LCT.
- the average value (absolute value) of the plasma insulin concentration increase in the LCT administration trial is 0.86 ⁇ 0.10 ng / ml
- the average value (absolute value) of the plasma insulin concentration increase in the MLCT (1) administration trial is Was 1.15 ⁇ 0.10 ng / ml.
- Test Example 2 Examination of insulin secretion promoting effect (2) Using rats fed with a glucose load, the plasma insulin secretion-promoting effect of the oil and fat composition of the present invention (MLCT) having a triacylglycerol composition different from that of Test Example 1 was examined using LCT as a control.
- MLCT oil and fat composition of the present invention
- Table 4 and Table 5 show the triacylglycerol composition and fatty acid composition of MLCT obtained in Production Example 3, respectively. The measurement was performed by the same method as described above.
- the test consists of an “LCT administration trial (sample 1 administration trial)” in which LCT is administered simultaneously with glucose load, and an “MLCT (2) administration trial (sample 3 administration trial) in which MLCT (2) is administered simultaneously with glucose load. ”In two trials. Samples 1 and 3 were orally administered to rats using a sonde. The dose was 6 ⁇ l / g rat body weight. The final dose was 2 g and 1 g of carbohydrate and lipid per 1 kg body weight of the rat, respectively.
- Plasma insulin concentration (ng / ml) was measured in the same manner as in Test Example 1.
- the test results are shown in FIG.
- the increase in plasma insulin concentration in the MLCT (2) administration trial was expressed as a relative value (%) where the average value of the increase in plasma insulin concentration in the LCT administration trial was 100, and expressed as an average value of relative values ⁇ standard error.
- the Student t-test test was used for the significant difference test between trials, and it was judged that there was a significant difference with a risk rate of less than 5%.
- the plasma insulin concentration increase in the MLCT (2) administration trial was significantly higher (p ⁇ 0.05) than in the LCT administration trial. Also from this, it became clear that secretion of insulin was promoted according to the transesterified oil (MLCT) of MCT and LCT.
- the average value (absolute value) of the plasma insulin concentration increase amount in the LCT administration trial is 1.25 ⁇ 0.10 ng / ml
- the average value (absolute value) of the plasma insulin concentration increase amount in the MLCT (2) administration trial was 1.50 ⁇ 0.14 ng / ml.
- D (+)-Glucose manufactured by Wako Pure Chemical Industries
- bovine serum albumin manufactured by SIGMA
- Example 1 administration trial in which LCT is administered simultaneously with glucose load
- MCT administration trial sample 4 administration trial
- Samples 1 and 4 were orally administered to rats using a sonde. The dose was 6 ⁇ l / g rat body weight. The final dose was 2 g and 1 g of carbohydrate and lipid per 1 kg body weight of the rat, respectively.
- Plasma insulin concentration (ng / ml) was measured in the same manner as in Test Example 1.
- the test results are shown in FIG.
- the amount of increase in plasma insulin concentration in the MCT administration trial was expressed as a relative value (%) where the average value of plasma insulin concentration increase in the LCT administration trial was 100, and the average value of the relative value ⁇ standard error.
- the Student t-test test was used for the significant difference test between trials, and it was judged that there was a significant difference with a risk rate of less than 5%.
- the average value (absolute value) of the increase in plasma insulin concentration in the LCT administration trial is 1.27 ⁇ 0.12 ng / ml
- the average value (absolute value) of the increase in plasma insulin concentration in the MCT administration trial is 1. It was 34 ⁇ 0.08 ng / ml.
- the test consists of an “LCT administration trial (sample 1 administration trial)” in which LCT is administered simultaneously with a glucose load, and an “MCT + LCT administration trial (sample 5 administration trial) in which a mixed oil of MCT and LCT is administered simultaneously with a sugar load. ”In two trials. Samples 1 and 5 were orally administered to rats using a sonde. The dose was 6 ⁇ l / g rat body weight. The final dose was 2 g and 1 g of carbohydrate and lipid per 1 kg body weight of the rat, respectively.
- Plasma insulin concentration (ng / ml) was measured in the same manner as in Test Example 1.
- the test results are shown in FIG.
- the amount of increase in plasma insulin concentration in the MCT + LCT administration trial was expressed as a relative value (%) where the average value of the amount of increase in plasma insulin concentration in the LCT administration trial was 100, and the average value of the relative value ⁇ standard error.
- the Student t-test test was used for the significant difference test between trials, and it was judged that there was a significant difference with a risk rate of less than 5%.
- the average value (absolute value) of the increase in plasma insulin concentration in the LCT administration trial is 1.28 ⁇ 0.18 ng / ml
- the average value (absolute value) of the increase in plasma insulin concentration in the MCT + LCT administration trial is 1. It was 25 ⁇ 0.18 ng / ml.
- the plasma insulin secretion-promoting effect observed in the transesterified oil (MLCT) of MCT and LCT is the same as that of triacylglycerol contained in MLCT. It was found to be due to triacylglycerols having one or two groups.
- MLCT transesterified oil
- Table 6 and Table 7 show the triacylglycerol composition and fatty acid composition of MLCT obtained in Production Example 6, respectively. The measurement was performed by the same method as described above.
- test feed is obtained in accordance with the formulation of the AIN 93 standard diet as fats and oils in LCT (trade name: Nisshin Canola Oil, Nisshin Oillio Group) or Production Example 6.
- LCT trade name: Nisshin Canola Oil, Nisshin Oillio Group
- Production Example 6 A feed designed using MLCT was used.
- Table 8 shows the composition of the test feed. First, after mixing each component other than fats and oils (LCT or MLCT), fats and oils were mixed and homogenized to obtain a test feed (LCT meal, MLCT meal).
- insulin resistance model rats (reference documents: Han et al, Diabetes, 46, p1761-p1767, 1997) were used. That is, Sprague-Dawley male rats (purchased from Japan SLC) were allowed to ingest insulin resistance by ingesting a high fat diet having the composition shown in Table 9 from the age of 4 weeks to 12 weeks of age. Using. During the breeding period, the fish is individually raised in a stainless steel mesh cage under the environment of a temperature of 23 ⁇ 1 ° C, humidity of 50 ⁇ 10%, and a 12-hour light / dark cycle (8:00 to 20:00 lighting), and water and high-fat feed. Was ad libitum.
- the above-mentioned 30 insulin resistance model rats were divided into 2 groups (15 each) so that the body weight, blood glucose level, and plasma insulin concentration were equalized, and the LCT food intake group (control group) And “MLCT food intake group” for ingesting MLCT food.
- Glucose C2 Test Wako manufactured by Wako Pure Chemical Industries, Ltd.
- Rat insulin ELISA kit Mercodia
- an insulin resistance model rat was ingested with test feed and bred for 6 weeks, and then an oral glucose tolerance test was conducted. The change in concentration over time was analyzed. That is, 1.5 g of glucose per kg body weight was orally administered to rats fasted overnight (16 hours), and from the tail vein of the rats before administration, 30 minutes, 60 minutes, and 120 minutes after administration. Blood was collected and blood glucose level and insulin concentration were measured.
- Glucose C2 Test Wako manufactured by Wako Pure Chemical Industries, Ltd.
- Rat insulin ELISA kit Mercodia
- the area under the curve (Area under the Curve: AUC) is calculated from a curve graph showing changes over time in blood glucose level and insulin concentration created based on the measured values, and the calculated values are the blood glucose level and plasma after glucose loading, respectively. Change amount of insulin concentration. Then, an average value and a standard error were calculated for the amount of change in each group, a significant difference test was performed between the groups using the Student t-test test, and it was judged that there was a significant difference with a risk rate of less than 5%. The results are shown in Table 10.
- adiponectin which has an action of enhancing insulin sensitivity from fat cells due to obesity, particularly accumulation of visceral fat, is not secreted normally (Kadowaki et al, J Clin Invest, 116, p1784-p1792, 2006). Therefore, changes in the secretion amount of adiponectin and the visceral fat amount accompanying improvement of insulin resistance in rats were examined.
- the measurement of plasma adiponectin concentration was performed on the above-mentioned rats after feeding the test feed and rearing for 6 weeks and before the oral glucose tolerance test. That is, blood was collected from the tail vein immediately before administration of glucose to rats, and the obtained blood was centrifuged at 3000 rpm for 10 minutes, and supernatant plasma was collected. The concentration of adiponectin in plasma was measured using an ELISA method (mouse / rat adiponectin ELISA kit, manufactured by Otsuka Pharmaceutical Co., Ltd.).
- the plasma adiponectin concentration was significantly higher in the MLCT diet intake group than in the LCT diet intake group. From this, it was considered that in the MLCT food intake group, secretion of adiponectin was restored by ingestion of MLCT, and insulin resistance was improved by the action of enhancing the insulin sensitivity of adiponectin.
- the visceral fat mass, the weight gain, and the test feed intake were measured for the rat after the oral glucose tolerance test.
- Rats fed with the test diet after the oral glucose tolerance test and reared for 2 days were killed by bleeding under anesthesia with diethyl ether.
- the epididymal fat, perinephric fat, and mesenteric fat were removed and each weight was measured, and the amount was determined as the amount of epididymal fat, perirenal fat, and mesenteric fat, respectively.
- the total fat mass of the epididymal fat mass, perirenal fat mass, and mesenteric fat mass was defined as the visceral fat mass.
- the amount of weight gain was calculated from the difference between the body weight at the start of administration of the test feed of each rat and the body weight immediately before dissection.
- the test feed intake was calculated as the average daily intake by measuring the total amount of test feed ingested by individual rats during the breeding period and dividing by the number of breeding days. Then, an average value and a standard error were calculated for the above-mentioned amounts in each group, and a significant difference test between the groups was performed using a Student t-test test, and it was judged that there was a significant difference with a risk rate of less than 5%.
- Table 12 shows the measurement results of the visceral fat mass
- Table 13 shows the measurement results of the weight gain and the test sample intake.
- the oil and fat composition of the present invention is effective in improving symptoms such as insulin secretion failure and insulin resistance found in diabetic patients, and can be used in the medical and food fields for diabetes.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
糖負荷を与えたラットを用いて、LCTを対照に、本発明の油脂組成物(MLCT)の血漿インスリン分泌促進効果を検討した。
40%グルコース(D(+)-Glucose,和光純薬社製)溶液10mlに、LCT(商品名:日清キャノーラ油,日清オイリオグループ社製)2gと、牛血清アルブミン(SIGMA社製)200mgとを添加し、得られた溶液を氷上で冷却しながら超音波処理(5分間を2セット、合計10分間)し、試料1を得た。対照として用いたLCT(商品名:日清キャノーラ油,日清オイリオグループ社製)の脂肪酸組成を表1に示す。
MCT(商品名:O.D.O,構成脂肪酸:n-オクタン酸/n-デカン酸=3/1,日清オイリオグループ社製)と、LCT(商品名:日清キャノーラ油,日清オイリオグループ社製)と、を14:86(質量比)の割合で混合し、混合油を得た。得られた混合油に、リパーゼ粉末を上記混合油に対して0.1質量%添加した後、60℃で15時間撹拌し、エステル交換反応させた。次いで、反応生成物からリパーゼ粉末を濾別し、濾液を水洗、乾燥後、脱色、脱臭して、MCTとLCTとのエステル交換油(MLCT(1))を得た。そして、40%グルコース(D(+)-Glucose,和光純薬社製)溶液10mlに、上記MLCT(1)2gと、牛血清アルブミン(SIGMA社製)200mgとを添加し、得られた溶液を氷上で冷却しながら超音波処理(5分間を2セット、合計10分間)し、試料2を得た。
糖負荷を与えたラットを用いて、LCTを対照に、試験例1とは異なるトリアシルグリセロール組成を有する本発明の油脂組成物(MLCT)の血漿インスリン分泌促進効果を検討した。
MCT(商品名:スコレー64G,構成脂肪酸:n-オクタン酸/n-デカン酸=3/2,日清オイリオグループ社製)と、LCT(商品名:日清コーン油,日清オイリオグループ社製)と、を30:70(質量比)の割合で混合し、混合油を得た。得られた混合油に対して、製造例2と同様の方法によりエステル交換反応、脱色処理、及び脱臭処理を施し、MCTとLCTとのエステル交換油(MLCT(2))を得た。そして、40%グルコース(D(+)-Glucose,和光純薬社製)溶液10mlに、上記MLCT(2)2gと、牛血清アルブミン(SIGMA社製)200mgとを添加し、得られた溶液を氷上で冷却しながら超音波処理(5分間を2セット、合計10分間)し、試料3を得た。
糖負荷を与えたラットを用いて、LCTを対照に、MCTの血漿インスリン分泌促進効果を検討した。
40%グルコース(D(+)-Glucose,和光純薬社製)溶液10mlに、MCT(商品名:O.D.O,構成脂肪酸:n-オクタン酸/n-デカン酸=3/1,日清オイリオグループ社製)2gと、牛血清アルブミン(SIGMA社製)200mgとを添加し、得られた溶液を氷上で冷却しながら超音波処理(5分間を2セット、合計10分間)し、試料4を得た。
糖負荷を与えたラットを用いて、LCTを対照に、MCTとLCTとの混合油(MCT+LCT)の血漿インスリン分泌促進効果を検討した。
MCT(商品名:O.D.O,構成脂肪酸:n-オクタン酸/n-デカン酸=3/1,日清オイリオグループ社製)と、LCT(商品名:日清キャノーラ油,日清オイリオグループ社製)と、を14:86(質量比)の割合で混合し、MCTとLCTとの混合油(MCT+LCT)を得た。そして、40%グルコース(D(+)-Glucose,和光純薬社製)溶液10mlに、上記混合油2gと、牛血清アルブミン(SIGMA社製)200mgとを添加し、得られた溶液を氷上で冷却しながら超音波処理(5分間を2セット、合計10分間)し、試料5を得た。
高脂肪食の長期間摂取によりインスリン抵抗性を発症したモデル動物を用いて、LCTを対照に、本発明の油脂組成物(MLCT)のインスリン抵抗性改善効果を検討した。
MCT(商品名:O.D.O,構成脂肪酸:n-オクタン酸/n-デカン酸=3/1,日清オイリオグループ社製)と、LCT(商品名:日清キャノーラ油,日清オイリオグループ社製)と、を14:86(質量比)の割合で混合し、混合油を得た。得られた混合油に、リパーゼ粉末を上記混合油に対して0.1質量%添加した後、60℃で15時間撹拌し、エステル交換反応させた。次いで、反応生成物からリパーゼ粉末を濾別し、濾液を水洗、乾燥後、脱色、脱臭して、本発明の油脂組成物であるMCTとLCTとのエステル交換油(MLCT)を得た。
試験飼料には、AIN93基準食の配合に準じ、油脂としてLCT(商品名:日清キャノーラ油,日清オイリオグループ社製)又は製造例6にて得られたMLCTを使用して設計した飼料を用いた。試験飼料の組成を表8に示す。まず、油脂(LCT又はMLCT)以外の各成分を混合した後、油脂を混合し、均一化して試験飼料(LCT食、MLCT食)を得た。
Claims (4)
- トリアシルグリセロールを有効成分として含有し、
当該トリアシルグリセロールは、分子内に中鎖脂肪酸残基を1つ又は2つ有し、且つ、構成脂肪酸として、炭素数6~10の中鎖脂肪酸と炭素数16~24の長鎖脂肪酸とを含有することを特徴とする糖尿病の予防又は治療用油脂組成物。 - 前記トリアシルグリセロールの構成脂肪酸は、炭素数6~10の中鎖脂肪酸と炭素数16~24の長鎖脂肪酸とからなる請求項1に記載の油脂組成物。
- 前記中鎖脂肪酸が炭素数8及び/又は10の飽和脂肪酸である請求項1又は2に記載の油脂組成物。
- 請求項1~3いずれか1項に記載の油脂組成物を含有する飲食品。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201180013481.4A CN102791264B (zh) | 2010-03-31 | 2011-03-22 | 用于预防或治疗糖尿病的油脂组合物 |
EP11762621.8A EP2554166B1 (en) | 2010-03-31 | 2011-03-22 | Oil and fat composition for the treatment of diabetes |
JP2012508220A JPWO2011122389A1 (ja) | 2010-03-31 | 2011-03-22 | 糖尿病の予防又は治療用油脂組成物 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010-081501 | 2010-03-31 | ||
JP2010081501 | 2010-03-31 | ||
JP2010-293961 | 2010-12-28 | ||
JP2010293961 | 2010-12-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011122389A1 true WO2011122389A1 (ja) | 2011-10-06 |
Family
ID=44712099
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2011/056710 WO2011122389A1 (ja) | 2010-03-31 | 2011-03-22 | 糖尿病の予防又は治療用油脂組成物 |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP2554166B1 (ja) |
JP (1) | JPWO2011122389A1 (ja) |
CN (1) | CN102791264B (ja) |
WO (1) | WO2011122389A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2671579A1 (en) * | 2011-01-31 | 2013-12-11 | The Nisshin Oillio Group, Ltd. | Fat and oil composition for promoting insulin secretion |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2922807A1 (en) * | 2013-09-02 | 2015-03-05 | The Nisshin Oillio Group, Ltd. | Chocolate |
MY173666A (en) * | 2013-09-06 | 2020-02-14 | Nisshin Oillio Group Ltd | Chocolate |
EP3369323B1 (en) * | 2015-10-26 | 2024-01-17 | The Nisshin OilliO Group, Ltd. | Oily food |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0692848A (ja) * | 1992-09-11 | 1994-04-05 | Sagami Chem Res Center | 糖尿病治療用乳剤 |
JP2000509258A (ja) * | 1996-04-12 | 2000-07-25 | ベス・イスラエル・デイーコネス・メデイカル・センター・インコーポレーテツド | 糖尿病用補足バー |
JP2002188096A (ja) * | 2000-10-12 | 2002-07-05 | Kanegafuchi Chem Ind Co Ltd | 新規なグリセリドおよびその製造法並びにその用途 |
JP2002193797A (ja) | 2000-12-22 | 2002-07-10 | Mitsukan Group Honsha:Kk | インスリン抵抗性改善用組成物 |
JP2002199844A (ja) * | 2000-12-28 | 2002-07-16 | Nisshin Oil Mills Ltd:The | 食用乳化油脂組成物 |
WO2004022051A1 (ja) * | 2002-09-05 | 2004-03-18 | The Nisshin Oillio Group, Ltd. | ペルオキシソーム増殖薬活性化受容体調整剤 |
US20040151757A1 (en) * | 2002-11-22 | 2004-08-05 | Horst Heirler Projekte Ernahrung * Medizin * Okologie | Use of medium-chain triglycerides (MCT) for optimisation as to nutrition physiology of the fatty acid spectrum in a dietary foodstuff for diabetics |
WO2004087199A1 (ja) | 2003-03-31 | 2004-10-14 | Fuji Oil Company, Limited | インスリン抵抗性改善用組成物 |
JP3677007B2 (ja) | 2002-03-13 | 2005-07-27 | 富士産業株式会社 | 抗糖尿病成分含有食品組成物 |
JP2007236348A (ja) * | 2006-03-10 | 2007-09-20 | Nisshin Oillio Group Ltd | 油脂組成物とその製造方法、水中油型乳化物、およびコンパウンドクリーム |
JP2008074734A (ja) | 2006-09-20 | 2008-04-03 | Unitika Ltd | インスリン抵抗性改善剤 |
WO2011024827A1 (ja) * | 2009-08-26 | 2011-03-03 | 日清オイリオグループ株式会社 | 嚥下・咀嚼困難者向け摂食補助用油脂組成物及び嚥下・咀嚼困難者用食品 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6835408B2 (en) * | 1998-11-13 | 2004-12-28 | The Nisshin Oillio Group, Ltd. | Oil or fat composition |
EP1481675A4 (en) * | 2002-03-04 | 2006-01-25 | Nisshin Oillio Group Ltd | MEDIUM FOR INCREASING BODY TEMPERATURE |
JP2004022051A (ja) * | 2002-06-14 | 2004-01-22 | Sharp Corp | 受光アンプ素子 |
JP2004022049A (ja) * | 2002-06-14 | 2004-01-22 | Fuji Photo Film Co Ltd | 磁気テープカートリッジ |
JP5739180B2 (ja) * | 2011-01-31 | 2015-06-24 | 日清オイリオグループ株式会社 | インスリン分泌促進用油脂組成物 |
-
2011
- 2011-03-22 JP JP2012508220A patent/JPWO2011122389A1/ja active Pending
- 2011-03-22 WO PCT/JP2011/056710 patent/WO2011122389A1/ja active Application Filing
- 2011-03-22 EP EP11762621.8A patent/EP2554166B1/en active Active
- 2011-03-22 CN CN201180013481.4A patent/CN102791264B/zh active Active
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0692848A (ja) * | 1992-09-11 | 1994-04-05 | Sagami Chem Res Center | 糖尿病治療用乳剤 |
JP2000509258A (ja) * | 1996-04-12 | 2000-07-25 | ベス・イスラエル・デイーコネス・メデイカル・センター・インコーポレーテツド | 糖尿病用補足バー |
JP2002188096A (ja) * | 2000-10-12 | 2002-07-05 | Kanegafuchi Chem Ind Co Ltd | 新規なグリセリドおよびその製造法並びにその用途 |
JP2002193797A (ja) | 2000-12-22 | 2002-07-10 | Mitsukan Group Honsha:Kk | インスリン抵抗性改善用組成物 |
JP2002199844A (ja) * | 2000-12-28 | 2002-07-16 | Nisshin Oil Mills Ltd:The | 食用乳化油脂組成物 |
JP3677007B2 (ja) | 2002-03-13 | 2005-07-27 | 富士産業株式会社 | 抗糖尿病成分含有食品組成物 |
WO2004022051A1 (ja) * | 2002-09-05 | 2004-03-18 | The Nisshin Oillio Group, Ltd. | ペルオキシソーム増殖薬活性化受容体調整剤 |
US20040151757A1 (en) * | 2002-11-22 | 2004-08-05 | Horst Heirler Projekte Ernahrung * Medizin * Okologie | Use of medium-chain triglycerides (MCT) for optimisation as to nutrition physiology of the fatty acid spectrum in a dietary foodstuff for diabetics |
WO2004087199A1 (ja) | 2003-03-31 | 2004-10-14 | Fuji Oil Company, Limited | インスリン抵抗性改善用組成物 |
JP2007236348A (ja) * | 2006-03-10 | 2007-09-20 | Nisshin Oillio Group Ltd | 油脂組成物とその製造方法、水中油型乳化物、およびコンパウンドクリーム |
JP2008074734A (ja) | 2006-09-20 | 2008-04-03 | Unitika Ltd | インスリン抵抗性改善剤 |
WO2011024827A1 (ja) * | 2009-08-26 | 2011-03-03 | 日清オイリオグループ株式会社 | 嚥下・咀嚼困難者向け摂食補助用油脂組成物及び嚥下・咀嚼困難者用食品 |
Non-Patent Citations (4)
Title |
---|
DENG, BIN ET AL.: "Effects of medium chain triglyceride on insulin resistance in type 2 diabetes mellitus", ZHONGHUA LINCHUANG YINGYANG ZAZHI, vol. 17, no. 3, 2009, pages 148 - 152, XP008162801 * |
HAN ET AL., DIABETES, vol. 46, 1997, pages 1761,1767 |
KADOWAKI ET AL., J CLIN INVEST, vol. 116, 2006, pages 1784 - 1792 |
STANDARD FAT AND OIL ANALYTICAL TEST METHODS (1996, 1996 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2671579A1 (en) * | 2011-01-31 | 2013-12-11 | The Nisshin Oillio Group, Ltd. | Fat and oil composition for promoting insulin secretion |
EP2671579A4 (en) * | 2011-01-31 | 2014-07-02 | Nisshin Oillio Group Ltd | OIL AND FAT COMPOSITION FOR PROMOTING INSULIN SECRETION |
Also Published As
Publication number | Publication date |
---|---|
EP2554166A1 (en) | 2013-02-06 |
EP2554166A4 (en) | 2015-03-11 |
JPWO2011122389A1 (ja) | 2013-07-08 |
CN102791264B (zh) | 2014-09-03 |
EP2554166B1 (en) | 2019-08-28 |
CN102791264A (zh) | 2012-11-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4391673B2 (ja) | 油脂組成物 | |
JP4031219B2 (ja) | 油脂組成物 | |
JP2007512407A (ja) | 共役リノール酸のジグリセライドの豊富な油脂組成物 | |
EP1430783A1 (en) | Oil/fat composition | |
TWI389697B (zh) | Improve the composition of lipid metabolism | |
WO2011122389A1 (ja) | 糖尿病の予防又は治療用油脂組成物 | |
EP2671579B1 (en) | Fat and oil composition for promoting insulin secretion | |
JP7520175B2 (ja) | 血中デカン酸濃度の上昇方法、血中デカン酸濃度上昇剤、医薬組成物、食品組成物 | |
JP2004075653A (ja) | 体脂肪分解促進剤および飲食物 | |
JP5702292B2 (ja) | パーキンソン病患者の内臓脂肪減少抑制剤 | |
JP2004210652A (ja) | 糖尿病患者における脂質代謝改善剤 | |
JP6084319B2 (ja) | インスリン分泌促進用食品 | |
JP6470879B1 (ja) | 抗炎症剤、抗炎症用医薬組成物、抗炎症用食品組成物 | |
JP2007045789A (ja) | 食後高インスリン血症改善剤 | |
EP2090176B1 (en) | Postprandial hyperglycemia-improving agent | |
JPWO2004022050A1 (ja) | 脂質代謝調整剤および飲食物 | |
WO2012073965A1 (ja) | インスリン分泌促進剤 | |
JP2012121823A (ja) | インスリン分泌促進剤 | |
JP2012126670A (ja) | インスリン分泌促進剤 | |
JP2005225863A (ja) | リパーゼ阻害剤 | |
JP2012116795A (ja) | インスリン分泌促進剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201180013481.4 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11762621 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012508220 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 8927/DELNP/2012 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011762621 Country of ref document: EP |